广泛区域淋巴结受累乳腺癌的多学科管理。
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
机构信息
University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Oncology, Mayo Clinic, Rochester, MN.
出版信息
J Clin Oncol. 2020 Jul 10;38(20):2290-2298. doi: 10.1200/JCO.19.03036. Epub 2020 May 22.
Abstract
Journal Journal of Clinical Oncology,
摘要
《临床肿瘤学期刊》
相似文献
1
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.广泛区域淋巴结受累乳腺癌的多学科管理。
J Clin Oncol. 2020 Jul 10;38(20):2290-2298. doi: 10.1200/JCO.19.03036. Epub 2020 May 22.
2
Late Recurrence Following Early Breast Cancer.早期乳腺癌的晚期复发。
J Clin Oncol. 2022 May 1;40(13):1400-1406. doi: 10.1200/JCO.22.00167. Epub 2022 Mar 3.
3
Late Breast Cancer Survivorship: Side Effects and Care Recommendations.晚期乳腺癌生存者：副作用和护理建议。
J Clin Oncol. 2022 May 20;40(15):1604-1610. doi: 10.1200/JCO.22.00049. Epub 2022 Feb 28.
4
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.改善激素受体阳性乳腺癌绝经前女性的辅助内分泌治疗方案调整
J Clin Oncol. 2020 Apr 20;38(12):1258-1267. doi: 10.1200/JCO.19.02242. Epub 2019 Oct 16.
5
Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.不再进行手术？IV期乳腺癌原发肿瘤的管理
J Clin Oncol. 2022 Mar 20;40(9):927-931. doi: 10.1200/JCO.21.02706. Epub 2022 Feb 4.
6
Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.CDK 抑制改善高危激素受体阳性乳腺癌的结局。
J Clin Oncol. 2022 Apr 10;40(11):1142-1146. doi: 10.1200/JCO.21.02850. Epub 2022 Feb 24.
7
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?内分泌治疗抵抗、激素受体阳性乳腺癌的选择：哪些靶点及何时？
J Clin Oncol. 2021 Dec 10;39(35):3890-3896. doi: 10.1200/JCO.21.01910. Epub 2021 Oct 28.
8
Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?是否所有患有导管原位癌的人都需要接受辅助放疗？
J Clin Oncol. 2021 Nov 10;39(32):3535-3540. doi: 10.1200/JCO.21.01896. Epub 2021 Oct 6.
9
Optimal Screening in Breast Cancer Survivors With Dense Breasts on Mammography.乳腺癌幸存者钼靶检查致密乳腺的最佳筛查方法。
J Clin Oncol. 2020 Nov 20;38(33):3833-3840. doi: 10.1200/JCO.20.01641. Epub 2020 Jul 24.
10
How We Monitor Cardiac Health in Breast Cancer Survivors.我们如何监测乳腺癌幸存者的心脏健康。
J Clin Oncol. 2025 Jan;43(1):4-9. doi: 10.1200/JCO.24.00757. Epub 2024 Sep 3.
引用本文的文献
1
Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer.免疫有效评分作为曲妥珠单抗新辅助治疗反应的预测因子和人表皮生长因子受体 2 阳性乳腺癌的预后指标。
Curr Oncol. 2022 Jan 10;29(1):283-293. doi: 10.3390/curroncol29010026.
2
Multidisciplinary Locoregional Management of Breast Cancer.乳腺癌的多学科局部区域管理
J Clin Oncol. 2020 Jul 10;38(20):2217-2219. doi: 10.1200/JCO.20.00483. Epub 2020 May 22.
本文引用的文献
1
Locoregional Management After Neoadjuvant Chemotherapy.新辅助化疗后的局部区域管理
J Clin Oncol. 2020 Jul 10;38(20):2281-2289. doi: 10.1200/JCO.19.02576. Epub 2020 May 22.
2
Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications.超过 1300 例保留乳头的乳房切除术即刻重建的结果：扩大适应证对并发症的影响。
Ann Surg Oncol. 2019 Oct;26(10):3115-3123. doi: 10.1245/s10434-019-07560-z. Epub 2019 Jul 24.
3
Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.新辅助化疗后乳腺癌腋窝残留淋巴结微转移和孤立肿瘤细胞的预后意义。
Ann Surg Oncol. 2019 Oct;26(11):3502-3509. doi: 10.1245/s10434-019-07517-2. Epub 2019 Jun 21.
4
Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial.接受新辅助化疗和腋窝淋巴结清扫的淋巴结阳性乳腺癌女性中，放疗对局部区域控制的影响：来自 ACOSOG Z1071 临床试验的结果。
Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):174-182. doi: 10.1016/j.ijrobp.2019.04.038. Epub 2019 May 11.
5
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.增加化疗剂量强度：通过更频繁的给药或序贯方案在 26 项随机试验中 37 298 例早期乳腺癌患者的个体水平荟萃分析。
Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8.
6
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.曲妥珠单抗-美坦新偶联物用于治疗残留浸润性 HER2 阳性乳腺癌。
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
7
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.ERBB2 阳性或三阴性乳腺癌患者低淋巴结阳性率与新辅助化疗后乳腺病理完全缓解的相关性。
JAMA Surg. 2018 Dec 1;153(12):1120-1126. doi: 10.1001/jamasurg.2018.2696.
8
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.以病理完全缓解为终点的乳腺癌临床试验中腋窝管理的手术标准
NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018.
9
Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.新辅助化疗治疗腋窝淋巴结阳性乳腺癌患者中腋窝清扫术的应用减少。
Ann Surg Oncol. 2018 Sep;25(9):2596-2602. doi: 10.1245/s10434-018-6637-9. Epub 2018 Jul 5.
10
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.全乳放射治疗：美国放射肿瘤学会（ASTRO）基于证据的指南执行摘要。
Pract Radiat Oncol. 2018 May-Jun;8(3):145-152. doi: 10.1016/j.prro.2018.01.012. Epub 2018 Mar 12.
Zotero 插件